News from provention bio, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 30, 2020, 16:30 ET Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the Stockholders

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today...

Jun 29, 2020, 07:00 ET Provention Bio Announces Inclusion in the Russell 3000 Index and Russell 2000 Index

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced...

Jun 22, 2020, 16:01 ET Provention Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today...

Jun 17, 2020, 22:16 ET Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced...

Jun 16, 2020, 16:01 ET Provention Bio Announces Proposed Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced...

Jun 15, 2020, 12:02 ET Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

May 28, 2020, 07:00 ET Provention Bio to Present at the Jefferies Virtual Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced...

May 20, 2020, 07:00 ET Provention Bio Announces Changes to its Board of Directors

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

May 18, 2020, 07:00 ET Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease and...

May 07, 2020, 16:05 ET Provention Bio Reports First Quarter 2020 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Apr 30, 2020, 07:00 ET Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Apr 16, 2020, 07:00 ET Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 16, 2020, 16:06 ET Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 12, 2020, 07:05 ET Provention Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 12, 2020, 07:00 ET Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 05, 2020, 07:00 ET Provention Bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, March 12, 2020

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...

Feb 19, 2020, 07:00 ET Provention Bio to Present at Upcoming Conferences

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Feb 06, 2020, 07:00 ET Provention Bio Highlights Critical New Research Studies on Type One Diabetes

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jan 08, 2020, 07:00 ET Provention Bio Appoints Jason Hoitt as Chief Commercial Officer

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Dec 12, 2019, 07:00 ET Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Nov 05, 2019, 16:05 ET Provention Bio Reports Third Quarter 2019 Financial Results

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Oct 29, 2019, 07:00 ET Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...

Oct 24, 2019, 07:00 ET Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Oct 22, 2019, 07:00 ET Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease,...

Sep 26, 2019, 07:00 ET Sean Doherty Joins Provention Bio Board of Directors

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...